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Abstract 
Background: Cholinergic neurons within the basal forebrain are assumed to be an early 
(preclinical) manifestation site of pathological changes in Alzheimer’s disease (AD). Aim: 
We used morphometric MRI to detect and quantify atrophic changes in the basal forebrain of 
subjects suffering from amnestic mild cognitive impairment (aMCI). Method: 3 Tesla MR 
data of 26 aMCI patients, 46 cognitively normal elderly controls (CO), and 12 patients 
suffering from Alzheimer’s dementia were analyzed, including segmentation and 
quantification of brain tissue as well as a segmentation of basal forebrain structures 
(substantia innominata, SI). Results: We found the volume of the SI to be significantly 
different between groups, in that control subjects showed the largest SI-volumes, followed by 
aMCI and AD-patients. Conclusion: These results are in line with the hypothesis that cell loss 
within the cholinergic basal forebrain regions occurs already in the early (predementia) stage 
of AD. Invivo quantification of these changes might be of use as a novel neuroimaging 
marker of cholinergic neurodegeneration in AD. 
 
Introduction 
Cholinergic dysfunction plays an important role in the cognitive impairment associated with 
Alzheimer’s disease (AD) (1). The magnocellular neurons of the nucleus basalis Meynert 
located in the substantia innominata (SI) of the basal forebrain are the main source of 
cholinergic projections to the cerebral cortex. Accordingly, previous MRI studies indicated 
atrophic changes of the basal forebrain in patients with clinically diagnosed AD (2, 3). Recent 
post-mortem studies demonstrated that pathological alterations of the cholinergic nuclei 
within the basal forebrain are already present in mild cognitive impairment (MCI), the 
putative transitional stage between normal aging and dementia (4, 5). While quantitative MRI 
has been widely used to investigate atrophy of the medial temporal lobe structures in MCI (6), 
little is kown about its feasibility to detect early SI changes in the predementia stages of AD. 
In this study we used in vivo morphometric methods to measure the volume of the SI in 
patients with MCI compared to AD-patients and cognitively normal elderly controls. We 
tested the hypothesis that MCI is characterized by volume loss of the SI which is detectable 
by MRI.  
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Methods. Twenty-six patients with aMCI (modified Petersen criteria) (7) were compared 
with 46 elderly control subjects and 12 AD-patients (NINCDS-ADRDA criteria) (Table1). All 
subjects underwent neuropsychological testing (Consortium to Establish a Registry for 
Alzheimer`s Disease (CERAD)) (8) to control for cognitive impairment, especially memory 
dysfunction. Only patients with amnestic MCI (with and without dysfunctions in additional 
cognitive domains) were included. In addition to clinical and neuropsychological 
investigations all participants were genotyped for APOE allele type using a standard 
polymerase chain reaction-based method. All MR examinations were performed on the same 
3.0 Tesla scanner (Trio; Siemens Medical System, Erlangen, Germany). The examination 
protocol included a high resolution T2-weighted sequence to image the SI-area using the 
following parameters: TR (repetition time) = 5000 ms, TE (echo time) = 137 ms, slice 
thickness = 1 mm, voxelsize = 0.5 x 0.5 x 1.0 mm), FOV field of view) = 256 mm, base 
resolution = 512. Additionally we performed a T1-weighted MPRAGE-Sequence (TR = 2300 
ms, TE = 3.93 ms, slice thickness = 1 mm, FOV = 256 mm, base resolution = 256) which was 
used for tissue segmentation and evaluation of global brain volume. 
 
 
The SI can be visualized as a narrow band below the globus pallidus and above the CSF 
contrast (Figure1). The structure-volume of the SI on both sides was measured on three 
coronar slices, 1mm before the anterior commisure (AC), through AC and 1 mm beyond AC. 
Relevant areas on each slice were manually traced, using a custom made segmentation 
program (vmr segmenter v0.8 by R. Schoenmeyer©) (9). Raters were blinded to group 
membership of the participants dataset.  Interrater reliability was established to be r = 0.82 
using an independent dataset. Detailed tracing guidelines including description of 
neuroanatomical landmarks can be provided by the authors on request. In addition to manual 
tracing, segmentation of the entire MR data sets into white matter (WM), gray matter (GM), 
and cerebrospinal fluid (CSF) was performed using the SPM5 package 
(http://www.fil.ion.ucl.ac.uk/spm/). Intracranial volume (ICV) was calculated by adding all 
three compartment volumes and used as a covariate for the statistical analysis. Statistical 
analyses was done with  SPSS 15.0 (SPSS Inc., Chicago, Ill., USA). The study was approved 
by the ethics committee of the University Hospital Frankfurt a.M. 
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Table 1: Groups characteristic    
 CO aMCI AD p 
N 46 26 12  
Age (y) 63.4 (6.4) 67.6 (6.7) 72.6 (6.6) <.001 a 
Sex (f/m) 27/19 14/12 6/6 n.s. a 
Education (y) 13.6 (2.4) 13.2 (2.5)  12.9 (2.7) n.s. a 
MMSE score 29.5 (0.8) 27.5 (1.8)  24.1 (4.2) <.001 a 
APOE ε4 carrier (%) 19.5 33.3 50.0 <.001 b 
Whole brain GM (%) 40.15 38.52 37.17 <.002 a 
Whole brain WM (%) 30.38 29.55 27.79 <.005 a 
CO, Control subjects; aMCI amnestic mild cognitive impairment;   
AD, Alzheimer´s Disease; MMSE, Minimental State Examination;   
APOE, Apolipoprotein E; a, ANOVA; b, χ2  test; n.s., not significant;   
GM, Grey matter, WM, White matter; values are means (+- standard deviation). 
 
 
Results. The volume of the SI was significantly different between groups (ANCOVA, p < 
0.001, F=11.38, df=4 using age and ICV as covariates, Bonferroni corrected; ANOVA 
F=32.22, df=2, Tukey test for multiple comparisons: controls vs. MCI p< 0.01, controls vs. 
AD p < 0.001, MCI vs. AD p < 0.05). In control subjects SI-extent was the largest (0.25 ± 
0.065 ccm), followed by a considerable loss of substance in the MCI group (0.19 ± 0.050 
ccm; -24% compared to controls) and a pronounced atrophy of the SI in the AD group (0.12 ± 
0.032 ccm; -52% compared to controls). In comparison to the SI-volume loss, global brain 
volume (GM, WM) in MCI and AD was less atrophied (Table 1) when compared between 
groups. (ANOVA, Tukey test for multiple comparisons; controls vs. AD, GM: F=6.90, df=2, 
p<.002; controls vs. AD WM: F=5.71, df=2, p<.002) . Data shown in figure 2 are mean values 
of both hemispheres. There was no difference between left and right SI volume for all groups. 
ApoE ε4 allele frequency (number of ε4 allele) differed (χ2 = 20.19, p = 0.0004) between 
groups: 50% of the AD-patients were ε4 positive. In MCI patients the frequency of ε4 was 
33.3% and control subjects only exhibited the ε4 allele in 19.5% of all cases. There were no 
within group differences of SI volume related to the presence or absence of the ε4 allele.  
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Exploratory testing for any relationship between cognitive function and volume of the SI 
revealed a correlation between performance in the word list recall task (CERAD subtest) and 
SI-volume in AD patients (r2=0.487, p<.037).  
 
Discussion. Degeneration of basal forebrain areas including the SI is a key event in the 
pathogenesis of AD. Accordingly, previous MRI studies reported atrophy of these areas in 
AD patients compared to elderly control subjects using one-dimensional measures of 
thickness (5) as well as voxel-based morphometry (VBM) (3). Hitherto there is only little 
evidence on measurable substance loss of the basal forebrain in the predementia stages of AD. 
Based on neuropathological findings it might be speculated that tissue loss of the SI can 
already be detected and quantified in patients with MCI (4, 5, 10, 11,12). These individulas 
are at an increased risk to develop AD and thus represent an important target group for 
(secondary) intervention measures for the prevention of dementia.    
 
Recently, Hall et al. (13) used VBM to identify atrophy of the medial basal forebrain in a 
subgroup of 21 cognitively healthy elderly participants of the Cardiovascular Health 
Cognition study who developed dementia at follow-up. In line with these findings our study 
for the first time demonstrates that volumetric MRI is a feasible tool to detect volume loss of 
the SI in vivo in a clinically characterized risk group for the development of AD (as defined 
be the aMCI concept). Our results are consistent with the hypothesis that there is already cell 
damage and neurodegeneration in the cholinergic basal forebrain region in subjects suffering 
from MCI. The presented findings are further in line with recent histological studies showing 
cytopathological changes in basal forebrain cholinergic neurons to be present very early in the 
aging-MCI-AD continuum (11). The recently published data of Zaborszky et al. (14) on 
probabilistic maps of the different magnocellular basal forebrain cell groups are of special 
interest to investigate distinct neurodegenerative processes within the SI-basal forebrain area 
using MRI. 
 
A further question addressed in our study was the influence of APOE ε4 status on volume loss 
in the SI. The APOE ε4 allele is a known risk factor for AD and the results of clinical trials 
using cholinergic substances suggest an influence of APOE ε4 status on therapeutic effects in 
AD and MCI (15, 16). Previous MRI studies found increased atrophy of medial temporal lobe 
regions in MCI patients positive for APOE ε4 (17). Similarly we suggested an influence of 
the genotype on SI volume between groups. So far we did not prove this relationship for the 
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basal forebrain region neither in patient groups (AD, MCI) nor in cognitively unimpaired 
elderly controls. However, since sample size is one limiting factor of our study this might 
explain these negative findings.   
 
In contrast to other morphometric studies on SI size which measured the thickness of the 
structure on a discrete slice, we used a volumetric approach to capture a larger portion of the 
SI. Furthermore, our method is characterized by its high neuroanatomical validity and should 
be less susceptible to post processing artifacts (which might easily be introduced when using 
automated measures such as VBM; 3,13). Our approach allowed to reliably quantify the 
volume loss of the SI in the diagnostic groups. The cross-sectional analysis revealed it to be –
24% in aMCI and –52% in the group of mildly demented AD patients (MMSE: 24.1 +4.2). 
This volume loss is considerably higher than values reported for medial temporal lobe atrophy 
in MCI and mild AD (6,18) and also much higher than our findings   for global brain atrophy 
(Table 1). These results refer to the basal forebrain region as an early neuronal correlate of 
degenerative processes in the CO-MCI-AD continuum. Accordingly, prospective longitudinal 
studies should clarify if our method can be used as a sensitive diagnostic marker of early 
(predementia) AD. In this context it is of special interest to clarify which area is the first to 
undergo pathological changes in terms of degeneration and MR detectable volume loss as 
well as to address potential correlations between neurodegeneration in basal forebrain 
structures and cortical volume loss in regions receiving cholinergic input. Based on our 
findings it would also be worthwhile to investigate the validity of SI atrophy as a predictor of 
therapeutic response in trials using cholinergic antidementia drugs or as a surrogate marker 
for the monitoring of cholinergic neurodegeneration during the course of the disease. 
 
 
 
 
 
 
 
  
 
 
Kathrin Muth 
 7 
Acknowledgement: This work was generously supported by the Alfried Krupp von Bohlen 
und Halbach foundation. We thank Professor Konrad Maurer for his valuable comments. 
 
Financial disclosure: None of the authors has to declare any conflict of interest 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References: 
(1) Whitehouse PJ, Price DL, Struble RG, Clark W, Coyle JT, Delon MR (1982):  Alzheimer's 
disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237-1239. 
 
(2) Hanyu H, Asano T, Sakurai H, Tanaka Y, Takasaki M, Abe K (2002): MR analysis of the 
substantia innominata in normal aging, Alzheimer disease, and other types of dementia. Am J 
Neuroradiol 23:27-32. 
 
Kathrin Muth 
 8 
(3) Teipel SJ, Flatz WH, Heinsen H, Bodke AL, Schönberg SO, Stöckel S et al. (2005): 
Measurement of basal forebrain atrophy in Alzheimer´s disease using MRI. Brain 28:2626-
2644. 
 
(4) Mufson EJ, Ma SY, Cochran EJ, Bennett DA, Beckettt LA, Jaffar S et al. (2000): Loss of 
nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive 
impairment and early Alzheimer´s disease. J Comp Neurol 427:19-30. 
 
(5) Mesulam M, Shaw P, Mash D, Weintraub S (2004): Cholinergic nucleus basalis tauopathy 
emerges early in the aging-MCI-AD continuum. Ann Neurol 55:815-828. 
 
(6) Pantel J, Kratz B, Essig M, Schröder J (2003): Parahippocampal volume reduction in 
aging- associated cognitive decline. Am J Psychiatry 160:379-382. 
 
(7) Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglione L, Wahlung LO et al. (2004): 
Mild cognitive impairment-beyond controversies, towards a consensus: report of the 
International Working Group on Mild Cognitive Impairment. J  Intern  Med  256:240-246. 
 
(8) Morris JC, Heymann A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G et al. (1989): 
The Consortium to Establish a Registry for Alzheimer´s Disease (CERAD). Part I Clinical 
and neuropsychological assessment of Alzheimer´s disease. Neurology 39:1159-1165. 
 
(9) Schönmeyer R, Prvulovic D, Rotarska-Jagiela A, Haenschel C, Linden DEJ (2006): 
Automated segmentation of lateral ventricles from human and primate magnetic resonance 
images using cognition network technology. Magn Reson Imaging 24:1377-1387. 
 
Kathrin Muth 
 9 
(10) Geula C, Nagykery N, Nicholas A, Wu CK (2008): Cholinergic Neuronal and Axonal 
Abnormalities are present early in aging and in Alzheimer Disease. J Neuropathol Exp Neurol 
67: 309-18. 
 
(11) Mesulam M, Shaw P, Mash D, Weintraub S (2004): Cholinergic nucleus basalis 
tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 55: 815-28. 
 
(12) Braak H, Del Tredici K (2004): Alzheimer’s dieseae: intraneuronal alterations precede 
insoluble amyloid-beta formation. Neurobiol Aging 25:713-718. 
 
(13) Hall AM, Moore RY, Lopez OL, Kuller L, Becker JT (2008): Basal forebrain atrophy is 
a presymptomatic marker for Alzheimer’s disease. Alzheimers Dement 4:271-279. 
 
(14) Zaborszky L, Hoemke L, Mohlberg H et al. (2008): Stereotaxic probabilistic maps of the 
magnocellular cell groups in human basal forebrain. Neuroimage 42: 1127-1141. 
 
(15) Choi SH, Kim SY, Na HR, Kim BK, Yang DW, Kwon JC et al. (2008): Effect of ApoE 
genotype on response to donepezil in patients with Alzheimer’s disease. Dement Geriatr 
Cogn Disord 25:445-450. 
 
(16) Petersen RC, Thomas RG, Grundmann M, Bennett D, Doody R, Ferris S et al. (2005): 
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 
352:2379-2388. 
 
(17) Mori E, Lee KU, Yasuda M et al. (2002): Accelerated hippocampal atrophy in 
Alzheimer´s disease with apolipoprotein E epsilon4 allele. Ann Neurol 51: 209-214. 
Kathrin Muth 
 10 
 
(18) Schuff N, Zhu XP (2007): Imaging of mild cognitive impairment and early dementia. Br 
J Radiol 80: 109-114. 
 
 
 
 
 
Table and figure legends: 
Table legend: 
Table 1. Group characteristics 
CO, Control subjects; aMCI amnestic mild cognitive impairment; AD, Alzheimer´s Disease; 
MMSE, Minimental State Examination; APOE, Apolipoprotein E; a, ANOVA; b, χ2  test; n.s., 
not significant; values are means (+- standard deviation). 
 
Figure legends: 
Figure 1. MR Imaging of the Substantia Innominata (SI). (A) Slice-group covering the SI, 
perpendicular to a plane through the anterior and posterior commisure. (B) coronar slice 
through the anterior commisure. (C) Comparison of SI-atrophy (arrow) between groups. 
 
Figure 2.  Boxplot of the Substantia Innominata Volume in patients with AD, MCI- and 
control subjects. The central box represents values from the 25th to the 75th percentiles; the 
middle line represents the median, and the horizontal line extends from the minimum to the 
maximum value. The median SI volume is lowest in the AD group compared with MCI and 
control subjects. CO, Control subjects; MCI, amnestic mild cognitive impairment; AD, 
Alzheimer´s Disease. Stars (*) indicate significant differences between groups; * p< 0.05, ** 
p< 0.01, *** p< 0.001. 
 
 
